Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trial.

Autor: Zaucha, J. M., Picardi, M., Kurlapski, M., Patti, C., Domingo‐Domenech, E., Sanz, R. Garcia, Rossi, A., Lopez‐jimenez, J., Trentin, L., Gotti, M., Viviani, S., Sorasio, R., Giza, A., Martinez‐Munoz, C., Nunez‐Cespedes, J., Filonenko, K., Chauvie, S., Guerra, L., Rambaldi, A., Sureda, A.
Předmět:
Zdroj: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p350-351, 2p
Abstrakt: B Conclusions: b LNM and MTV, both assessed in baseline PET/CT, turned out as the most frequently used tools to guide treatment in RAFTING trial, superseding PET-2 and possibly paving the way to future eHL Tx options based on new metrics in baseline PET/CT. B Introduction: b The efficacy of combined-modality treatment (Tx) with chemotherapy (CT) and radiotherapy (RT) in early-stage Hodgkin Lymphoma (eHL) is offset by long-term morbidity, with a cumulative incidence of 2nd primary malignancy at 40 years of 48.5% (Schaapveld 2015). Baseline-PET derived metrics are the most relevant factors for risk stratification in early-stage nonbulky HL: preliminary results of the RAFTING trial. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: